tru Independence’s Karyopharm Therapeutics KPTI Stock Holding History

tru Independence’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10	Closed	-$3	–	612
2020 Q2	$3	Buy	+10	New	+$2.96K	﹤0.01%	763

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

tru Independence's KPTI Position: Q3 2020 in Review

tru Independence sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 10 shares — an estimated $3 sold.

tru Independence first reported a position in KPTI in Q2 2020 and held it in 1 quarter. The position peaked at $3 in Q2 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

tru Independence reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
tru Independence sold 10 Karyopharm Therapeutics shares in Q3 2020, an estimated $3.
tru Independence first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 1 quarter.
tru Independence's Karyopharm Therapeutics position peaked at $3 in Q2 2020.
157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.